IL198250A0 - Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b - Google Patents

Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b

Info

Publication number
IL198250A0
IL198250A0 IL198250A IL19825009A IL198250A0 IL 198250 A0 IL198250 A0 IL 198250A0 IL 198250 A IL198250 A IL 198250A IL 19825009 A IL19825009 A IL 19825009A IL 198250 A0 IL198250 A0 IL 198250A0
Authority
IL
Israel
Prior art keywords
dimethoxy
isobutyl
substituted
Prior art date
Application number
IL198250A
Other languages
English (en)
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39110526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL198250(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of IL198250A0 publication Critical patent/IL198250A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL198250A 2006-11-08 2009-04-21 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b IL198250A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86494406P 2006-11-08 2006-11-08
PCT/US2007/084176 WO2008058261A1 (en) 2006-11-08 2007-11-08 Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto

Publications (1)

Publication Number Publication Date
IL198250A0 true IL198250A0 (en) 2009-12-24

Family

ID=39110526

Family Applications (1)

Application Number Title Priority Date Filing Date
IL198250A IL198250A0 (en) 2006-11-08 2009-04-21 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b

Country Status (16)

Country Link
US (2) US8039627B2 (OSRAM)
EP (1) EP2081929B1 (OSRAM)
JP (1) JP5290185B2 (OSRAM)
KR (1) KR101500766B1 (OSRAM)
CN (1) CN101553487B (OSRAM)
AU (1) AU2007317242B2 (OSRAM)
BR (1) BRPI0718247B1 (OSRAM)
CA (1) CA2668689C (OSRAM)
DK (1) DK2081929T3 (OSRAM)
EA (1) EA018378B1 (OSRAM)
ES (1) ES2402220T3 (OSRAM)
IL (1) IL198250A0 (OSRAM)
MX (1) MX2009004910A (OSRAM)
PL (1) PL2081929T3 (OSRAM)
PT (1) PT2081929E (OSRAM)
WO (1) WO2008058261A1 (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0718247B1 (pt) 2006-11-08 2021-09-21 Neurocrine Biosciences, Inc. Composto usado como inibidor do transportador de monoamina vesicular 2, composição farmacêutica compreendendo o dito composto e uso da dita composição farmacêutica no tratamento de transtornos hipercinéticos
AU2009303758B8 (en) 2008-09-18 2015-02-19 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2012000308A1 (zh) * 2010-06-29 2012-01-05 中国药科大学 丁苯那嗪的拆分方法
US8351329B2 (en) * 2010-09-14 2013-01-08 Cisco Technology, Inc. Universal load-balancing tunnel encapsulation
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
WO2014047167A1 (en) 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3421469A1 (en) * 2013-01-31 2019-01-02 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2015048370A1 (en) * 2013-09-27 2015-04-02 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
HK1224222A1 (zh) 2013-12-03 2017-08-18 Auspex Pharmaceuticals, Inc. 制造苯并喹啉化合物的方法
AU2015209330A1 (en) 2014-01-27 2016-07-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2938244A1 (en) 2014-02-07 2015-08-13 Auspex Pharamaceuticals, Inc. Novel pharmaceutical formulations
JP6718376B2 (ja) 2014-02-07 2020-07-08 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
MX387625B (es) * 2014-05-06 2025-03-18 Neurocrine Biosciences Inc Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos.
MX375718B (es) * 2015-02-06 2025-03-06 Neurocrine Biosciences Inc [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
EA201791977A1 (ru) 2015-03-06 2018-01-31 Оспекс Фармасьютикалз, Инк. Способы лечения патологических непроизвольных движений
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
JP6919099B2 (ja) * 2015-06-23 2021-08-18 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
BR112018007118A2 (pt) 2015-10-09 2018-12-11 Teva Pharmaceuticals Int Gmbh método para tratar um distúrbio de deficiência de dopamina, método para melhorar o tempo motor ativo sem discinesia num paciente com doença de parkinson, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir o tempo motor inativo num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir flutuações de nível de dopamina estriatal num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina após um tratamento de longo prazo, composição farmacêutica e embalagem
HUE053872T2 (hu) * 2015-10-30 2021-07-28 Neurocrine Biosciences Inc Valbenazin-ditozilát és polimorfjai
MA44127A (fr) 2015-12-23 2018-10-31 Neurocrine Biosciences Inc Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
WO2017182916A1 (en) * 2016-04-22 2017-10-26 Lupin Limited Novel process for preparation of tetrabenazine and deutetrabenazine
EP3473623B1 (en) * 2016-06-29 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of nbi-98854, preparation method therefor and use thereof
WO2018067945A1 (en) * 2016-10-06 2018-04-12 Assia Chemical Industries Ltd. Solid state forms of valbenazine
EP4400171A3 (en) 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
KR20200066662A (ko) 2017-01-27 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2020508337A (ja) 2017-02-27 2020-03-19 サンド・アクチエンゲゼルシヤフト バルベナジン塩の結晶形態
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
EA201992168A1 (ru) 2017-03-15 2020-03-16 Ауспекс Фармасьютикалз, Инк. Аналоги деутетрабеназина, их получение и применение
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
EP3606530A2 (en) * 2017-04-01 2020-02-12 Adeptio Pharmaceuticals Limited Dihydrotetrabenazine for use in the treatment a movement disorder
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JOP20190239A1 (ar) * 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
MY198713A (en) * 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
EP3706748A4 (en) * 2017-11-08 2021-08-11 Foresee Pharmaceuticals Co., Ltd. ESTER OF DIHYDROTETRABENAZINE
RU2020117345A (ru) 2017-11-22 2021-12-23 Ассиа Кемикал Индастриз Лтд Твердая форма валбеназина
WO2019129100A1 (zh) 2017-12-26 2019-07-04 苏州科睿思制药有限公司 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
CN110092785A (zh) * 2018-01-31 2019-08-06 广东东阳光药业有限公司 一种丁苯那嗪的动态拆分方法
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
EA202092750A1 (ru) * 2018-06-14 2021-05-13 Ньюрокрайн Байосайенсиз, Инк. Соединения ингибиторы vmat2, композиции и способы, относящиеся к ним
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020070236A1 (en) 2018-10-04 2020-04-09 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
CA3065236A1 (en) 2018-12-27 2020-06-27 Apotex Inc. Novel crystalline form of valbenazine dibesylate
WO2020213014A1 (en) 2019-04-19 2020-10-22 Mylan Laboratories Limited An improved process for the preparation of valbenazine and its salts
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
WO2021027792A1 (zh) * 2019-08-12 2021-02-18 山东绿叶制药有限公司 Vmat2抑制剂及其制备方法和应用
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN114423755A (zh) 2019-09-13 2022-04-29 纽罗克里生物科学有限公司 用于合成缬苯那嗪的方法
CN110698397A (zh) * 2019-10-28 2020-01-17 南京红杉生物科技有限公司 丁苯那嗪中间体及其合成方法、应用和合成用中间产物
SI4168409T1 (sl) 2021-03-22 2025-08-29 Neurocrine Biosciences, Inc. Inhibitorji VMAT2 in postopki njihove uporabe
US20240239791A1 (en) 2021-04-26 2024-07-18 Neurocrine Biosciences, Inc. Processes for the synthesis of valbenazine
CA3221728A1 (en) 2021-06-30 2023-01-05 Grace S. LIANG Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
US20240342159A1 (en) 2021-06-30 2024-10-17 Neurocrine Biosciences, Inc. Valbenazine for use in the add-on treatment of schizophrenia
WO2023172849A1 (en) 2022-03-07 2023-09-14 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
IL319670A (en) 2022-09-21 2025-05-01 Neurocrine Biosciences Inc VMAT2 inhibitors based on hexahydro-2H-pyridyl-1,2-[A]isoquinoline and methods of use
WO2025038938A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Valbenazine for use in the treatment of huntington's chorea
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025188830A1 (en) 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025199234A1 (en) 2024-03-20 2025-09-25 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
US3209005A (en) 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US2852518A (en) 1957-05-23 1958-09-16 Parke Davis & Co Di-substituted quinoline compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
EP1907017A4 (en) 2005-06-29 2011-05-04 Univ Columbia USE OF DTBZ FOR THE PRESENTATION OF ENDOCRINE PANCREAS AND BETAZELL MASS IN DIABETES TYPE 1
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
HRP20090074T3 (en) 2005-08-06 2009-04-30 Cambridge Laboratories (Ireland) Limited 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
BRPI0718247B1 (pt) 2006-11-08 2021-09-21 Neurocrine Biosciences, Inc. Composto usado como inibidor do transportador de monoamina vesicular 2, composição farmacêutica compreendendo o dito composto e uso da dita composição farmacêutica no tratamento de transtornos hipercinéticos

Also Published As

Publication number Publication date
KR101500766B9 (ko) 2024-09-25
EA200970461A1 (ru) 2009-12-30
US8039627B2 (en) 2011-10-18
PT2081929E (pt) 2013-04-15
CA2668689A1 (en) 2008-05-15
MX2009004910A (es) 2009-07-24
PL2081929T3 (pl) 2013-06-28
EP2081929A1 (en) 2009-07-29
EP2081929B1 (en) 2013-01-09
JP2010509366A (ja) 2010-03-25
CN101553487B (zh) 2012-06-13
US8357697B2 (en) 2013-01-22
WO2008058261A1 (en) 2008-05-15
ES2402220T3 (es) 2013-04-29
ES2402220T8 (es) 2021-12-23
CN101553487A (zh) 2009-10-07
BRPI0718247A2 (pt) 2014-01-07
DK2081929T3 (da) 2013-04-15
US20120077839A1 (en) 2012-03-29
EA018378B1 (ru) 2013-07-30
KR20090079257A (ko) 2009-07-21
BRPI0718247B1 (pt) 2021-09-21
AU2007317242B2 (en) 2013-08-01
US20080167337A1 (en) 2008-07-10
AU2007317242A1 (en) 2008-05-15
CA2668689C (en) 2015-12-29
KR101500766B1 (ko) 2015-03-16
JP5290185B2 (ja) 2013-09-18

Similar Documents

Publication Publication Date Title
IL198250A0 (en) Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b
IL192799A0 (en) Substituted 4-phenylpiperidines
ZA200903382B (en) Substituted 4-imidazoles
IL194972A0 (en) 2-alkoxy-3,4,5-trihydroxy-alkylamide-
GB0606655D0 (en) Showerpod 1
GB0615059D0 (en) Corcost 506
GB0604313D0 (en) MoveClick 14
GB0603565D0 (en) Moveclick 11
GB0603050D0 (en) Moveclick 10
GB0603759D0 (en) MoveClick 12
GB0604112D0 (en) Moveclick 13
GB0604311D0 (en) Corcost 2
GB0604312D0 (en) Corcost 3
GB0615050D0 (en) Corcost 706
GB0604493D0 (en) Corcost 4
GB0604494D0 (en) Corcost 5
GB0703783D0 (en) 75
GB0604523D0 (en) Corcost 3
GB0604578D0 (en) Corcost 6
GB0619930D0 (en) Corcost 0031
GB0619890D0 (en) Corcost 0020
GB0615357D0 (en) Corcost 2006
GB0615330D0 (en) Corcost 2006
GB0604621D0 (en) Corcost 8
GB0602974D0 (en) Moveclick 9

Legal Events

Date Code Title Description
FF Patent granted
KB20 Patent renewed for 20 years